Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Question/Statement, on a post on X dated 9/14, it stated that they were in talks with a new IR firm, I am hoping that this is the same one,
Is it me or are the suppressing the stock for a big hit, yall thoughts,
10Q filed per Twitter.
$NTRR closing in on the Acquisition of Mercury Clinical Research out of Houston TX any day now w/ 2022 Gros Revs of $4 Million Dollars! Values NTRR on this acquisition alone 3-4x its current PPS https://mercurycr.us.com,,,,,,twitter post 6/9/2023,,,FYI
I think September is a long way off, especially when they had issues with the last earning report. I need to review their postings on twitter and other 8k's before I has a solid answer, my impression it was going to be June 2023, but being wrong here is a cottage industry,
Press Releases
Presentations
IR Calendar
Email Alerts
Propanc Biopharma’s Intellectual Property Portfolio Makes Important Advancements in Europe
DOWNLOAD AS PDFMay 25, 2023
PRP Dosing Patent Validated in 12 Countries Across Europe & Method to Treat Cancer Stem Cells Receives Notice of Allowance from European Patent Office
MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTC Pink: PPCBD) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s intellectual property (IP) portfolio made important advancements in Europe. The dosing patent, describing claims for the dosing regimen of the Company’s lead product candidate, PRP, has now been validated in 12 countries across Europe. In further news, the Company’s method to treat cancer stem cells (CSCs) using PRP received a notice of allowance from the European Patent Office (EPO). This is the third patent allowed, or granted to the Company in Europe, with further applications under examination by the EPO.
As a result of validating the dosing patent in this major global region, Propanc now has enforceable patent rights in the UK, France, Germany, Spain, Italy, Denmark, Belgium, Czech Republic, Sweden, Switzerland/ Liechtenstein and Ireland. In 2022, the worldwide pharmaceutical market was valued at approximately $1.48 trillion by Statista.com and Europe accounted for 23.4% of global pharmaceutical sales in 2021, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA). As a result of validating the dosing patent across Europe, the Company’s IP portfolio has grown to 76 patents either allowed, or granted in major jurisdictions around the world.
For the allowed CSCs patent, the claims cover a method to minimize the progression of cancer in a patient who has already received a first line treatment by detecting the presence of CSCs followed by administering PRP. This patent describes the clinical application of PRP when the patient experiences a relapse and the cancer returns after primary standard of care has been applied.
“The advancement and growth of our IP portfolio represents a cornerstone for our company as we progress PRP towards entering the clinical development phase and our next major milestone,” said James Nathanielsz, BAS, MEI, Propanc’s Chief Executive Officer. “We have reached out to potential licensing partners and identified a potential suitor who expressed interest to see results from our planned Phase I, First-In-Human study in advanced cancer patients. Having an established IP portfolio with a novel, first-in-class therapy for the treatment and prevention of metastatic cancer has us well placed to seek a licensing partner for PRP, as we progress to the next major development milestones, which we hope to achieve in the not-too-distant future.”
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include kidney, ovarian, breast, brain, prostate, colorectal, lung, liver, uterine, and skin cancers.
Tue, May 23, 2023 at 8:30 AM EDT
In this article:
PPCB
+54,750.00%
Watchlist
Watchlist
PPCBD
+109,600.00%
PRP Foundation Patent Receives Notice of Allowance from Canadian Intellectual Property Office & Method to Treat Cancer Stem Cells Granted by the US Patent & Trademark Office
MELBOURNE, Australia, May 23, 2023--(BUSINESS WIRE)--Propanc Biopharma, Inc. (OTC Pink: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s intellectual property (IP) portfolio achieved significant milestones in North America. The foundation patent, covering composition claims for the Company’s lead product candidate, PRP, received a notice of allowance from the Canadian Intellectual Property Office (CIPO). In further news, the Company’s method to treat cancer stem cells (CSCs) using PRP was granted a patent by the United States Patent and Trademark Office (USPTO). This is the third patent granted to the Company in the US, with further applications under examination by the USPTO.
The Canadian foundation patent is the final application in the Company’s foundation patent family to achieve allowance. This means that allowance or grant status has been secured in every jurisdiction in which the Company filed a foundation patent application. Propanc has an accepted application or achieved grant status for the foundation patent in over 30 different countries across North America, Europe, Asia, the Middle East and Japan.
For the US granted CSCs patent, the claims cover a method to minimize the progression of cancer in a patient who has already received a first line treatment by detecting the presence of CSCs followed by administering PRP. This patent describes the clinical application of PRP when the patient experiences a relapse and the cancer returns after primary standard of care has been applied.
"The milestones achieved for our intellectual property portfolio in North America are highly significant, as we now have patents in force in every jurisdiction selected by the Company for future commercialization of PRP," said James Nathanielsz, BAS, MEI, Propanc’s Chief Executive Officer. "This represents perseverance and 15 years of hard work to reach a stage where we have established our IP portfolio. Our technology is a novel approach for the treatment and prevention of metastatic cancer from solid tumors, which is the leading cause of death for sufferers. Our therapy is free from side effects normally associated with standard treatment approaches, based off our limited clinical experience from treatment. We look forward to advancing PRP to a First-In-Human study in advanced cancer patients to further establish the benefits of this first-in-class treatment."
Dr Julian Kenyon, MD, MB, ChB, Propanc’s Chief Scientific Officer, said, "More than 15 years ago, we determined to find a way to patent this unique treatment approach for cancer sufferers based on an initial investigation at my clinical practice. I believe PRP can become an important treatment approach to control the spread of solid tumors by targeting CSCs. We are very interested in possible clinical applications of PRP, such as treating resistant tumors post standard therapy, or as a chemo-sensitizing agent. We expect to continue to grow and expand our intellectual property portfolio whilst advancing PRP into the clinic to establish proof of concept in a target patient population, and identify a suitable partner for licensing."
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include kidney, ovarian, breast, brain, prostate, colorectal, lung, liver, uterine, and skin cancers.
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (the "Company") is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian, and colorectal cancers. For more information, please visit www.propanc.com.
The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.
To view the Company’s "Mechanism of Action" video on its anti-cancer lead product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the patents and planned studies and treatments described above and the successful execution of the Company’s business strategy. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process; the availability of financing; the Company’s ability to implement its long range business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary business partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the SEC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005567/en/
Contacts
Investor Relations and Media:
Mr. James Nathanielsz
Propanc Biopharma, Inc.
irteam@propanc.com
+61-3-9882-0780
Question, if after the split and it goes back down to trips, any of you guys going to get back in,
Check again....
This was filed 06/09/2022, DEF-14C, I wanted to point out some verbiage, the stock split is not FOR CERTAIN, let's play this out,
The Reverse Stock Split will be effected, if at all, only upon a determination by the Board that a Reverse Stock Split (at a Reverse Stock Split ratio determined by the Board, but not to exceed 1-for-1,000) is then in the best interests of the Company and its stockholders. The Board’s determination as to whether the Reverse Stock Split will be effected and, if so, at what ratio, will be based upon certain factors, including existing and expected marketability and liquidity of our Common Stock, prevailing market conditions and the likely effect on the market price of our Common Stock. If the Board determines to effect the Reverse Stock Split, the Board will consider various factors in selecting the ratio, including the overall market conditions at the time and the recent trading history of the Common Stock. Notwithstanding approval of the Reverse Stock Split by the Majority Stockholder, the Board may, in its sole discretion, abandon the Reverse Stock Split and the Certificate of Amendment and determine prior to the effectiveness of the filing of the Certificate of Amendment with the Secretary of State of the State of Delaware not to effect the Reverse Stock Split, as permitted under Section 242(c) of the DGCL.
From ChatAI:
Orphan Drug Designation is a status granted by regulatory agencies, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), to drugs or biologics intended to treat rare diseases or conditions that affect a small number of people. The designation provides certain incentives and benefits to drug developers to encourage the development of treatments for rare diseases, which might otherwise not be commercially viable.
To qualify for orphan drug designation, a drug or biologic must meet certain criteria, such as having a prevalence of the disease in the target population of no more than 5 in 10,000 individuals in the US, or no more than 5 in 10,000 individuals in the European Union. Additionally, the drug must demonstrate promise in treating the rare disease, either through preclinical or clinical data.
Once a drug has been granted orphan drug designation, the drug developer may be eligible for various incentives, such as tax credits for clinical research expenses, exemption from certain FDA fees, and exclusive marketing rights for a period of time after the drug is approved. These incentives are intended to encourage the development of treatments for rare diseases, which might not otherwise be pursued due to the small market size and high development costs.
A notice of effectiveness is a formal notification from the U.S. Securities and Exchange Commission (SEC) that a company's registration statement has been reviewed and declared effective. This means that the company can now move forward with its planned securities offering, such as an initial public offering (IPO), and begin selling its securities to the public.
The notice of effectiveness is a critical milestone for a company that is seeking to raise capital through the sale of securities. It signals to investors that the company has met all of the regulatory requirements for the offering and has been approved by the SEC.
The SEC typically reviews a company's registration statement to ensure that it contains all of the necessary information for investors to make informed investment decisions. This includes information about the company's business, financial performance, and risks associated with the investment.
Once a company receives a notice of effectiveness, it can begin the process of selling its securities to the public. However, the company must still comply with ongoing reporting requirements and other regulatory obligations to maintain its status as a publicly traded company.
Why was the stock halted at 7p this evening
It will not be a buyout more than likely, they will sign an exclusive licensing deal with a Big Pharma Glaxo-Smith-Kline, much easier and less expensive for the company's doing business with them.
8k Released 4:20p on 3/17/2023. Definition supplied by Chat AI
A Certificate of Retirement of preferred stock is a document issued by a company to indicate that a certain series or class of preferred stock has been retired or redeemed. Preferred stock is a type of stock that typically pays a fixed dividend to shareholders and has priority over common stock in the event of the company's liquidation or bankruptcy.
When a company decides to retire or redeem a particular series or class of preferred stock, it will typically issue a Certificate of Retirement to the holders of the stock to inform them of the action. The certificate will typically include information such as the name of the company, the series or class of preferred stock that has been retired, the date of the retirement, and the amount of the dividend or redemption payment to be made to the shareholders.
Retiring or redeeming preferred stock can have several implications for both the company and the shareholders. For example, retiring preferred stock can reduce the company's debt and interest payments, while redeeming preferred stock can provide shareholders with cash and potentially increase the value of remaining shares.
Regenerate response
The Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2023, would subject hemp extract products to the regulatory framework for dietary supplements; while the CBD Product Safety and Standardization Act of 2023, would establish regulations for CBD as a food and beverage additive.
Someone just purchased 50m
Chatgpt ai
Propanc Biopharma Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing new treatments for various forms of cancer. The company is based in the United States, with headquarters in New York.
Propanc's lead product candidate is PRP, a proprietary formulation of pancreatic proenzymes that has shown promising results in preclinical and early clinical studies. The company believes that PRP has the potential to become a new standard of care for pancreatic and other forms of cancer.
In addition to PRP, Propanc is also developing other novel cancer therapies based on its proprietary proenzyme technology platform. The company's pipeline includes product candidates for the treatment of ovarian, colorectal, and prostate cancers, among others.
Propanc's mission is to provide new and effective treatments for cancer patients, with a focus on improving survival rates and quality of life. The company is committed to advancing its pipeline of products through rigorous clinical trials and regulatory approvals, and to collaborating with leading cancer research institutions and healthcare providers around the world.
My thinking is they get the approval of this new therapeutic drug, they would license it out to one of the Big Pharmas, collect millions a month. It is easier.
It's more likely that they sign a licensing deal with Big Pharma, they have the patents, that is where the money is,
Sell High, my inkling on this, it would be a great licensing deal from a Big Pharma Co, they have the patents, easy deal as well,
They did a SS in 2020, that was the reason I had them on my radar, can they do one, yes, will they do one, maybe, but that is the risk we take,
Consolidated Last Sale $0.0002 undefined undefined
After-Hours Volume 25,000,000
After-Hours High $0.0002 (04:00:08 PM)
After-Hours Low $0.0002 (04:00:08 PM)
From Nasdaq.Com
Therapeutic Goods Administration (TGA) (Australia's version of the FDA) are they as strict as the FDA, as to approving new drug's if anyone knows?
Per last year, a Q will come out on or about 2/14, last year, 2/14/2022, end date 12/31/2021.
Novel proenzyme therapy is a type of treatment that involves the use of proenzymes, which are inactive precursors of enzymes. The idea behind this therapy is that by administering a proenzyme, it will be activated within the body to perform its desired enzymatic function. This approach is being researched for a variety of diseases and conditions, such as cancer, inflammation, and metabolic disorders, as a way to potentially achieve therapeutic benefits with improved safety compared to traditional enzyme-based therapies. However, it is important to note that this type of therapy is still in the early stages of development and more research is needed to fully understand its potential benefits and drawbacks.
That is my issues as well, they speak on financing public and private, worrying.
Dammit,